Amarin Corporation plc (AMRN) Company Overview

What does Amarin Corporation do?

Amarin Corporation plc is a cardiovascular pharmaceutical company built around one active ingredient: icosapent ethyl. Sold as VASCEPA in the United States and VAZKEPA in much of Europe, it is used with statins to reduce cardiovascular risk in specified high-risk adults with elevated triglycerides. In the U.S., it is also approved with diet for severe hypertriglyceridemia.

Amarin is not a diversified drug company. It is a single-product platform whose economics depend on evidence, payer access, branded share, generic competition, partner execution, manufacturing cost, and spending discipline. Its official company overview describes a direct U.S. commercial model and an indirect international model that uses partners across close to 100 markets.

The core asset and the patient need

The case rests on REDUCE-IT and the regulatory and guideline recognition that followed. Amarin reported recognition by more than 70 medical societies and over 30 million cumulative prescriptions by June 2026. This evidence is more valuable than a triglyceride-lowering claim alone, although it does not remove competition. The company’s June 2026 medical update also shows the product’s widening geographic availability.

How does Amarin make money from a one-product cardiovascular franchise?

Amarin reports product revenue and licensing or royalty revenue. Product revenue includes U.S. branded sales and supply shipments to European and rest-of-world partners. In Q1 2026, product revenue was $43.3M and licensing and royalty revenue was $1.8M, so reported sales remained overwhelmingly product-led.

Why the U.S. remains the economic engine

U.S. net revenue reflects wholesaler shipments less rebates, discounts, returns, and other deductions. Amarin controls execution directly but faces generic icosapent ethyl and concentrated payer negotiations. In Q1 2026, U.S. revenue was flat even as branded prescriptions rose 17% and market share improved to about 48% from 42%. Price, channel inventory, rebates, and customer mix therefore matter as much as volume.

How the partner model changes international economics

International expansion is designed to be less capital intensive. Under the 59-country Recordati agreement, Amarin supplies finished product while Recordati commercializes it. The model widens access without rebuilding a large local sales force, but lowers direct control and makes results dependent on partner launches, reimbursement, forecasts, and order timing.

Which turning points explain Amarin’s current strategy?

Amarin’s model reflects evidence creation, label expansion, patent disruption, and commercial redesign. It built a differentiated clinical case, lost much of the U.S. exclusivity that could monetize it, and is now preserving demand while shifting fixed selling costs to partners.

1. 2012–2013
   FDA approval and the U.S. launch created the platform for later cardiovascular expansion.
2. 2018
   REDUCE-IT reported about a 25% relative reduction in major cardiovascular events, transforming the product into an outcomes asset.
3. 2019
   The FDA expanded the label for cardiovascular risk reduction.
4. 2020
   A patent ruling and unsuccessful appeal opened the U.S. market to generics and weakened price protection.
5. 2024
   Aaron Berg became CEO, emphasizing execution, cost control, and cash preservation.
6. 2025
   Amarin entered the 59-country Recordati collaboration and reduced direct European infrastructure.
7. 2026
   Amarin reported higher branded share, lower expense, and two positive-cash-flow quarters while remaining GAAP loss-making.

Why the 2020 patent outcome changed the business

Generic entry did not erase the evidence, but it weakened Amarin’s ability to capture its value. Competition shifted toward payer placement, branded access, contracting, supply, and net price. The moat is therefore commercial and evidence-based rather than a patent wall. The company’s 2025 Form 10-K.

What does Amarin’s latest quarter show?

Q1 2026 showed improving demand and cost discipline but a sharp margin trade-off. Revenue rose 7% to $45.1M and operating expenses fell 31% to $29.1M. Yet COGS rose 62% to $27.4M because of customer mix, payer-related shipments, and international supply. Cash flow improved while product gross margin weakened.

What changed in demand and market share?

The U.S. icosapent ethyl market grew 3%, branded VASCEPA prescriptions increased 17%, and Amarin’s share rose to about 48% from 42%. This suggests payer access can regain volume in a generic market. However, U.S. revenue stayed near $35.6M, so prescription growth did not translate one-for-one into net revenue.

Why did margin fall while cash flow improved?

Product gross margin fell from roughly 59% in Q1 2025 to 37% in Q1 2026, while SG&A fell 42% to $21.1M. Amarin is accepting lower unit economics in some channels while removing fixed commercial cost to improve cash conversion. The official Q1 2026 results release and Form 10-Q provide the underlying period figures.

Profitability, cash flow, and the new operating model

Amarin’s balance sheet is stronger than its income statement because it holds substantial cash and investments and reports no debt. At March 31, 2026, cash and short-term investments were $307.8M, current assets were $626.0M, current liabilities were $179.6M, and equity was $449.4M. This funds the transition but does not replace sustainable profitability.

Can the balance sheet fund the transition?

The near-term answer is yes, but liquidity is not all excess cash. Inventory of $183.6M was large relative to quarterly revenue and must convert without write-downs or demand shortfalls. Receivables of $108.1M also make collections important. Three customers represented 87% of Q1 2026 gross product sales, increasing sensitivity to wholesaler behavior.

How has capital allocation changed?

Capital allocation has shifted toward restructuring, partner support, core medical evidence, and cash preservation. FY2025 included $36.2M of restructuring charges; management said $31M of an expected $70M savings program had been realized by year-end. R&D was $19.8M, supporting the existing product and required science rather than a broad late-stage pipeline. The FY2025 results package shows the scale of that redesign.

What gives Amarin a competitive advantage, and where is the moat thin?

Amarin’s strongest resource is the combination of outcomes evidence, regulatory labeling, physician familiarity, and accumulated use. REDUCE-IT is more defensible than a triglyceride-lowering claim alone. The cardiovascular indication, guideline recognition, and more than 30 million cumulative prescriptions support prescriber confidence and payer access.

Evidence-based differentiation

This evidence acts like a brand asset because clinicians and payers understand the therapy’s role. It is not exclusive intellectual property: generics use the same active ingredient and payers can favor lower-cost alternatives. Amarin must defend branded volume through coverage, contracting, supply, continuity, and labeled cardiovascular differentiation.

Which competitors pressure the business?

Who owns AMRN, and why did the 2026 shareholder vote matter?

Amarin has dispersed ownership rather than founder control, but Sarissa Capital has material influence. The 2026 proxy disclosed 33.47 million shares, or 7.98%, for Sarissa. Directors and officers as a group owned 18.10 million shares, or 4.21%. CEO Aaron Berg held about 3.41 million shares, and Michael Torok held 4.85 million, or 1.16%.

Economic ownership and board structure

Why the May 2026 vote is financially relevant

At the May 13, 2026 meeting, about 70% of entitled shares were represented. Shareholders rejected four proposals, including certain issuance authority and a 15 million-share incentive-plan increase. Amarin said the failed plan proposal could constrain equity grants and push compensation toward cash, affecting expense and retention. The 2026 definitive proxy explains ownership and board structure, while the annual-meeting Form 8-K records the vote.

Which opportunities could improve Amarin’s story?

The credible opportunities are commercial and operational: regain U.S. branded share, convert payer access into net revenue, scale partner markets, normalize margin, and complete the cost reset.

The highest-value growth and efficiency levers

Amarin also said it was evaluating strategic alternatives with Barclays. This is not evidence that a transaction will occur. The stand-alone business should be valued first, with any deal treated as an uncommitted option.

What risks could weaken Amarin’s outlook?

Amarin’s risks are concentrated because nearly every major variable traces to one product. Changes in access, prescribing, price, manufacturing, reimbursement, or safety perception affect the whole company. Cash provides time but does not diversify exposure.

The most material filing-based risks

In the cardiovascular outcomes study, hospitalization for atrial fibrillation or flutter occurred in 3% of VASCEPA patients versus 2% with placebo, and bleeding occurred in 12% versus 10%. These established label considerations matter because clinicians must continue to view the benefit-risk profile favorably.

Why does Amarin’s business model matter for valuation?

A simple revenue multiple is a poor fit because value depends on U.S. economics, international partners, gross-margin mix, restructuring savings, working capital, and net cash. A DCF should separate operating value from cash and model several branded-demand paths.

Which DCF inputs matter most?

Terminal value deserves caution. Clinical evidence is durable, but the franchise faces generic substitution and lacks a broad pipeline. A conservative case can assume U.S. erosion partly offset by international sales. A favorable case requires sustained share, stable net price, partner launches, and normalized expense; a downside case includes faster price compression and working-capital drag.

Which KPIs should students and investors monitor next?

Amarin should be monitored as an operating transition. The useful dashboard combines demand, price, margin, expense, cash, and partner execution. Prescription growth matters only if it supports net revenue and gross profit; lower spending matters only if commercial and medical execution remain intact.

The next release should be compared with Q1 2026 and the Recordati transition schedule. Europe becomes more informative once partner-model periods are comparable. Cash stability should also be tested after excluding temporary working-capital benefits.

What is the key takeaway from Amarin Corporation analysis?

Amarin has a clinically meaningful product, strong evidence, broad guideline recognition, and a liquid debt-free balance sheet. Its constraints are one-product concentration, generic competition, uneven channel economics, partner dependence, working capital, and GAAP losses.

The question is whether higher branded share and lower expense can create durable gross profit and free cash flow. Q1 2026 showed progress through 7% revenue growth, 31% lower operating expense, and $6.4M of operating cash inflow, but gross profit and margin still fell on mix.